Douglas Kerr, Chief Medical Officer of Dyne Therapeutics, Inc., filed a Form 4 on September 8, 2026, reporting two automatic sales of common stock on September 4 and September 8, 2026, to satisfy tax withholding obligations tied to vesting restricted stock units.

Key Highlights

  • First sale: 3,745 shares of common stock were disposed of on September 4, 2026, at a weighted average price of $24.35, within a range of $24.27 to $24.50.
  • Second sale: 1,290 shares were disposed of on September 8, 2026, at a weighted average price of $18.88, within a range of $18.77 to $18.92.
  • RSU vesting sources: The September 4 sale relates to RSUs granted on September 3, 2024; the September 8 sale relates to RSUs granted on December 4, 2024.
  • Post-transaction ownership: Following the reported transactions, Kerr directly beneficially owns 162,564 shares, including 125,126 unvested RSUs.
  • Rule 10b5-1 plan: Both sales were made pursuant to binding RSU agreements constituting affirmative defense contracts under Rule 10b5-1(c) and, according to the filing, "do not represent a discretionary trade by the Reporting Person."

Dyne Therapeutics CMO Share Disposals: RSU Tax Withholding Details

According to the Form 4 filed with the SEC, Douglas Kerr, Chief Medical Officer of Dyne Therapeutics, Inc. (NASDAQ:DYN), reported two separate disposals of common stock in connection with the vesting of restricted stock units. The filing indicates both transactions were automatic sales, not discretionary trades, executed to cover tax withholding obligations arising from RSU vesting events.

The first transaction, dated September 4, 2026, involved the disposal of 3,745 shares at a weighted average price of $24.35. The filing discloses that these shares were sold in multiple transactions at prices ranging from $24.27 to $24.50, inclusive. This sale was tied to RSUs originally granted on September 3, 2024. Following this transaction, Kerr's reported beneficial ownership stood at 163,854 shares held directly.

The second transaction, dated September 8, 2026, involved the disposal of 1,290 shares at a weighted average price of $18.88, with individual transaction prices ranging from $18.77 to $18.92, inclusive. This sale was connected to RSUs granted on December 4, 2024. After this transaction, Kerr's directly held beneficial ownership was reported as 162,564 shares, of which 125,126 are identified in the filing as unvested RSUs. The filing notes that full information regarding shares sold at each separate price within either range is available upon request to the issuer, any security holder, or SEC staff.

What Was Disclosed

The filing reports two automatic share disposals by Dyne Therapeutics' Chief Medical Officer to cover RSU-related tax withholding on September 4 and September 8, 2026, totaling 5,035 shares, with post-transaction direct beneficial ownership of 162,564 shares including 125,126 unvested RSUs.